1. Experimental efficacy of an everolimus eluting cobalt chromium stent
- Author
-
Lori Gibson, Andrew J. Carter, Chi-An Wang, Sarah Ross, Leslie Coleman, Scott Haller, Anastasia Brodeur, Renu Virmani, and Robin Collingwood
- Subjects
medicine.medical_specialty ,Swine ,medicine.medical_treatment ,Cobalt chromium stent ,Urology ,Coronary Angiography ,Prosthesis Design ,Coronary Restenosis ,Random Allocation ,Drug Delivery Systems ,Restenosis ,medicine ,Animals ,Bare metal ,Radiology, Nuclear Medicine and imaging ,Everolimus ,cardiovascular diseases ,Cell Proliferation ,Sirolimus ,business.industry ,Stent ,General Medicine ,equipment and supplies ,medicine.disease ,Coronary Vessels ,Surgery ,Coronary arteries ,Stenosis ,surgical procedures, operative ,medicine.anatomical_structure ,Research Design ,Models, Animal ,Feasibility Studies ,Stents ,Chromium Alloys ,Tunica Intima ,Cardiology and Cardiovascular Medicine ,business ,Immunosuppressive Agents ,medicine.drug - Abstract
Introduction: Rapamycin and its analogs are now being coated on different stent platforms, using different polymer matrices to prevent restenosis by impairing vascular smooth muscle cell proliferation and neointimal formation. Methods: We evaluated the feasibility and compared the efficacy of biostable polymeric everolimus and sirolimus (CYPHER®, Cordis) eluting stents in a porcine coronary model. Cobalt chromium balloon expandable stents (ML VISION®, Guidant) were coated with a polymer containing everolimus (190 μg/cm2). Twelve pigs underwent placement of 36 oversized sirolimus (n = 12), everolimus (n = 12), and bare metal (cobalt chromium, n = 12) stents in the coronary arteries. Results: At day 28, vessel injury scores were low (
- Published
- 2006